We are excited to collaborate with Biogen on litifilimab,” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “Royalty Pharma offers tailored, win-win funding solutions for ...
Ubrelvy and Nurtec are prescription medications taken to treat migraines. Though they share similarities, Ubrelvy is for ...
Total proceeds of $530 million on $300 million original 2022 investment Proceeds strengthen balance sheet and provide added flexibility to pursue ...
Nebraska will receive $62,688.71. Biohaven is accused of giving health care providers cash and lavish meals to get them to prescribe Nurtec ODT, a migraine medication. The company also paid some ...
Pfizer will pay nearly $60 million to settle claims that its subsidiary Biohaven used illegal kickbacks to drive sales of its migraine medicine Nurtec ODT … ...
Pfizer paid $11.6bn to buy Biohaven, largely on the financial performance of Nurtec ODT. The drug went on to generate global sales of $928m in sales in 2023. Known as Vydura in Europe, Nurtec ODT ...
Biohaven knowingly caused the submission of false claims to Medicare and other federal health care programs by paying kickbacks to health care providers to induce prescriptions of Biohaven’s drug ...
Nurtec ODT, also known as Rimegepant, was approved for treating acute migraine in February 2020 and its approval was extended to preventing episodic migraine in June 2021. The drug was promoted by ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback